Clinical TrialsSearch results
Number of results: 482
Other
- A retrospective study on aphasia therapy
- Cerebrovascular disease Traumatic brain injury
- Japan Society for Higher Brain Dysfunction
- 2009-07-15
Other
- Japan endometrioma malignant transformation study
- endometriosis
- Japan Society of Obstetrics and Gynecology
- 2009-04-13
Other
- Safety and efficacy of FOLFOX plus bevacizumab or FOLFIRI plus bevacizumab as second line Therapy in Advanced colorectal Cancer previously treated with bevacizumab.
- advanced colorectal cancer
- Japan South West Oncology Group
- 2009-08-28
Other
- Phase II study of Chemotherapy for Advanced or Recurrent Thymoma
- Thymoma (excluding thymic carcinoma)
- Japanese Association for Research on the Thymus
- 2006-04-01
Other
- Phase II Study of Thymomectomy for Thymoma Localized in the Thymus
- thymoma
- Japanese Association for Research on the Thymus
- 2007-04-01
Other
- An open-label, randomized, controlled study of treatment duration of peginterferon alpha-2a monotherapy in patients with chronic hepatitis C
- Chronic hepatitis C with genotype 2a/2b or genotype 1b and low viral load (< 100 KIU/mL)
- Japanese Consortium for the Study of Liver Diseases
- 2008-03-31
Other
- A randomized controlled study comparing S-1 with UFT as postoperative adjuvant Chemotherapy in Rectal Cancer.
- Rectal Cancer
- Japanese Foundation for Multidisciplinary Treatment of Cancer
- 2006-04-01
Other
- An Open-Label Randomized Phase III Study of Capecitabine(6 months) versus Capecitabine(12 months) as Adjuvant Chemotherapy for Stage III(Dukes'C) Colon Cancer Patients.
- Colon cancer
- Japanese Foundation for Multidisciplinary Treatment of Cancer
- 2008-09-10
Other
- Clinical efficacy of Daikenchuto (DKT: TJ-100) for gastrointestinal dysfunction following colon surgery (a randomized, double-blind, multi-center, placebo-controlled study)
- Colon cancer including RS cancer
- Japanese Foundation for Multidisciplinary Treatment of Cancer
- 2009-01-01
Other
- Phase II study of neoadjuvant treatment with Exemestane for 24 weeks in postmenopausal women with hormone receptor positive Stage II or IIIA breast cancer.
- Breast Cancer
- Japanese Foundation for Multidisciplinary Treatment of Cancer
- 2006-03-06